TORONTO--(BUSINESS WIRE)--Medworxx Inc. (“Medworxx”) (TSXV: MWX), a leader in clinical utilisation review solutions, announced today that the NHS England has completed its 2014/15 Commissioning for Quality and Innovation Schedules (CQUIN). The schedules are contractual requirements for providers, one of the schedules included is titled “Patient Flow improvement through Clinical Utilisation Review.” This CQUIN demonstrates NHS England’s commitment to CUR as an essential tool to effective patient flow and provides NHS Hospital Trusts with risk free set-up funding and ongoing financial support and incentives to develop and embed robust Clinical Utilisation Review systems. Funding will bemade available to providers undertaking initial baseline “Diagnostic Utilisation Reviews” using a recognized UR tool, with further significant support for training, licensing and implementation of full embedded CUR solutions.
The NHS England CQUIN publication states:
“Utilisation review has been Department of Health policy for the NHS since 2006 and is a key feature of health systems delivering quality outcomes with lower levels of acute hospital use. A number of English hospitals have implemented UR clinical software applications to reduce admission rates, improve flow and discharge as well as, with commissioners, right-size capacity in step down and community services to match clinical need.
The financial and quality case for providers for implementing this change is compelling; this CQUIN provides additional incentive and allows for early adoption without financial risk to providers until the sustainable gains can be shown to be delivering an on-going return on investment that outweighs the costs of change.
NHS England direct commissioners are encouraged to apply the CQUIN to priority areas of care for specialised services and assess potential for a jointly funded scheme with CCG commissioners for greater reach across all inpatient services where this fits local priorities.”
Over the last 12 months, 15 English hospitals have seen early adoption success with the Medworxx Clinical Utilisation Review. Medworxx clients in Liverpool, Middlesbrough, East Midlands, North Surrey and Central South have been recognised for their pioneering work in this area, particularly Liverpool who received the eHI Award for the Most Innovative Example of IT Enabled Change for their case manager model using the Medworxx Clinical Utilisation Review solution.
In the UK, Medworxx works in conjunction with Greater East Midlands (GEM) Clinical Support Unit (CSU) and Model Advice DC Consulting in undertaking Diagnostic Utilisation Reviews and the implementation of Clinical Utilisation Review solutions.
Peter Ellis, Managing Director of Medworxx UK stated, “This CQUIN is unique in providing hospitals a direct financial incentive to adopt a validated patient flow improvement solution. The NHS has built an unprecedented payment structure that will help providers establish a baseline and implement quick win changes. This demonstrates the value the NHS places on the application of evidence based objective criteria in ensuring appropriate patient care whilst identifying opportunities for whole system transformation.”
“The concept of using a Clinical Utilisation Review type product is relatively new in the UK marketplace,” said Dan Matlow, CEO and President, Medworxx. “As a clinical utilisation software provider, it is gratifying to note that the NHS recogonises the value in these offerings and has created attractive financial incentives to accelerate the adoption rate.”
Medworxx delivers health information technology solutions to over 350
hospitals internationally, including Canada, United States, United
Kingdom, France and Australia. Medworxx helps hospitals meet patient
flow challenges and requirements in compliance and education. Medworxx
Clinical Criteria —flagship of Medworxx Patient Flow that includes
electronic bed management and independent assessment
components—currently serves over 35% of the acute-care beds in Canada,
and a rapidly increasing number of Trusts and CCGs in the UK. Founded in
2004, Medworxx Inc. is based in Toronto, ON, and publicly traded on the
TSX Venture Exchange: MWX.
About Greater East Midlands CSU
Established in 2010, GEM is the NHS Clinical Support Unit (CSU) that
supports and works on behalf of the 20 Clinical Commissioning Groups
(CCGs) in the East Midlands area. These CCGs serve a population of over
4.500,000 and fund the provider trusts with over 9,000 medical, surgical
and community beds and 4,000 mental health places. GEM service redesign
team uses the Medworxx Clinical Criteria to conduct clinical utilisation
reviews, snapshot audits and ongoing embedded reviews. Medworxx Patient
Flow provides GEM with the tools for system redesign, demand capacity
and planning to help ensure that, during the audit, all patients in the
region are receiving the right care at the right time in the right
place. GEM is now in a consortium with North Yorkshire and Humberside
CSU, West Yorkshire, South Yorkshire and Bassetlaw CSU and Arden CSU.
About Model Advice DC
ModelAdvice is a partner of Medworxx and has extensive experience in
undertaking Clinical Utilisation Reviews using the Medworxx software and
realigning processes and accountability to exploit CUR systems. MADC
provides specialised consulting advice and consultation, guidance for
NHS and other health care organisations. Their toolkits and systems have
been developed for the NHS and Department of Health requirements.
ModelAdvice has over 60 years of experience in health care process
improvement, Payment-by-Results and PBC program management required now
in the UK under the NHS Agenda. With a wealth of talent, ModelAdvice is
able to work closely with the client to design and implement changes
through methodology that is practical and workable in order to gain
improvement in the customer’s environment.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.